Company intelligence / Profile preview

Cellistic

Mont-Saint-Guilbert, Belgiumcellistic.com ↗

Ownership: Private
Development stage: Phase 1

Overview

Cellistic provides proprietary iPSC-based platforms—Pulse™ for rapid generation of edited iPSC lines and Echo™ for scalable GMP manufacturing of differentiated immune effector cells. The company’s technologies are designed to accelerate timelines from concept through IND-enabling studies. Clinical results pertain to partner programs enabled by these platforms rather than in-house therapeutics.

Therapeutic areas: Oncology
Modalities: Induced pluripotent stem cell (iPSC)-based cell therapiesAllogeneic cell therapiesImmune cell therapies (NK cells, α/β T cells, γ/δ T cells, macrophages)
Industry: Drug Discovery Services

Partnerships

Not specifically named, but works with multiple autologous and allogeneic cell therapy developers as contract development/manufacturing partner.

Beyond the preview

Go deeper on Cellistic.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cellistic.

Explore the full profile